MedPath

Solid Biosciences Inc.

Solid Biosciences Inc. logo
🇺🇸United States
Ownership
Public
Established
2014-01-01
Employees
101
Market Cap
$353.1M
Website
http://www.solidbio.com

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Phase 1
Recruiting
Conditions
Duchenne Muscular Dystrophy
Interventions
Genetic: SGT-003
First Posted Date
2023-11-18
Last Posted Date
2024-12-16
Lead Sponsor
Solid Biosciences Inc.
Target Recruit Count
6
Registration Number
NCT06138639
Locations
🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

🇺🇸

University of California, Los Angeles Medical Center, Los Angeles, California, United States

🇺🇸

University of California, Davis, Sacramento, California, United States

and more 3 locations

Evaluation of Home Based Assessments on Participants With DMD

Completed
Conditions
Duchenne Muscular Dystrophy
Interventions
Device: Wearable Device
Other: Duchenne Video Assessment (DVA)
First Posted Date
2022-12-20
Last Posted Date
2023-08-14
Lead Sponsor
Solid Biosciences Inc.
Target Recruit Count
17
Registration Number
NCT05657938
Locations
🇺🇸

Solid Biosciences, Charlestown, Massachusetts, United States

Microdystrophin Gene Transfer Study in Adolescents and Children With DMD

Phase 1
Active, not recruiting
Conditions
Duchenne Muscular Dystrophy
Interventions
Genetic: SGT-001
First Posted Date
2017-12-11
Last Posted Date
2024-12-10
Lead Sponsor
Solid Biosciences Inc.
Target Recruit Count
12
Registration Number
NCT03368742
Locations
🇺🇸

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

🇺🇸

University of Florida, Gainesville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath